Dr. Jing PAN's team's research paper “CD22 CAR-T cell therapy in refractory or relapsed B acute lymphoblastic leukemia” was officially included and published in Leukemia, the world's top academic Journal.
To date, 19 clinical trials on CD22 CAR-T have been registered in the Clinical Trials worldwide. Following the first publication of therapeutic data by the National Cancer Institute (NCI) in Nature Medicine in 2018, this paper of Dr. Chunrong TONG and Jing PAN's team is the second one on CD22 CAR-T cell therapy for B-ALL published worldwide.
This means that in the field of CD22 CAR-T, the research achievements of the Chinese team have been recognized for the first time in the global academic field and represent the world's most advanced research level. Leukemia is the world's most authoritative academic journal in the field of hematology, with a SCI impact factor of 10.023. This is the research team led by Director Chunrong TONG in Beijing Boren Hospital that published academic achievements in the Leukemia twice in two years. Dr. Jing PAN is the first author of this selected paper, and Director Chunrong TONG is the corresponding author.